{
    "Trade/Device Name(s)": [
        "ADVIA Centaur Digoxin assay",
        "ADVIA Centaur\u00ae Digoxin assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics, Inc.",
    "510(k) Number": "K193397",
    "Predicate Device Reference 510(k) Number(s)": [
        "K931213"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "KXT"
    ],
    "Summary Letter Date": "October 16, 2020",
    "Summary Letter Received Date": "October 19, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3320"
    ],
    "Regulation Name(s)": [
        "Digoxin Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Digoxin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur XP system"
    ],
    "Method(s)/Technology(ies)": [
        "Competitive immunoassay",
        "Direct chemiluminescent"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur Digoxin assay for quantitative determination of digoxin in serum and plasma using ADVIA Centaur XP systems",
    "Indications for Use Summary": "For in vitro diagnostic use in the quantitative determination of digoxin in serum and plasma (EDTA and lithium heparin) using the ADVIA Centaur XP systems to aid in diagnosis and treatment of digoxin overdose and to monitor digoxin therapy",
    "fda_folder": "Toxicology"
}